Aspirin and nonsteroidal anti-inflammatory drug hypersensitivity

Clinical Reviews in Allergy and Immunology

Volumn 32, Issue 1, 2007, Pages 97-109

  Kong, James S W ^a   Teuber, Suzanne S ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse events; Anaphylactoid; Anaphylaxis; Angioedema; Arachadonic acid; Aspirin; Aspirin exacerbated respiratory disease; Cyclooxygenases; Hypersensitivity; Leukotrienes; Nonsteroidal anti inflammatory drugs; Sensitivity; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HEPARIN; IMMUNOGLOBULIN E; LIPOXYGENASE; MAGNESIUM SALICYLATE; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; ROFECOXIB; SALICYLIC ACID; TICLOPIDINE;

AGING; ALLERGIC PNEUMONITIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONFERENCE PAPER; CONJUNCTIVA DISEASE; CORONARY ARTERY DISEASE; COUGHING; CROSS REACTION; DESENSITIZATION; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG ELUTING STENT; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; ENZYME INHIBITION; EOSINOPHILIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPOTENSION; IN-STENT RESTENOSIS; LARYNX SPASM; LOW DRUG DOSE; LOWER RESPIRATORY TRACT; LUNG INFILTRATE; MONOTHERAPY; NOSE CONGESTION; NOSE POLYP; PERCUTANEOUS CORONARY INTERVENTION; PERIORBITAL EDEMA; PNEUMONIA; RESPIRATORY TRACT DISEASE; RHINITIS; RHINORRHEA; RISK FACTOR; SINUSITIS; STOMACH PAIN; SYMPTOM; THORAX PAIN; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT; URTICARIA; WHEEZING;

EID: 34247150645     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02686086     Document Type: Conference Paper

References (62)

1. Szczeklik, A. and Stevenson, D. D. (1999), Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 104(1), 5-13.
2. Stevenson, D. D. (2004), Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 24(3), 491-505, vii.
3. Masubuchi, Y., Yamada, S., and Horie, T. (2000), possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 292(3), 982-987.
4. Ji, B., Masubuchi, Y., and Horie, T. (2001), possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes. Pharmacol Toxicol 89(1), 43-48.
5. Stevenson, D. D., Sanchez-Borges, M., and Szczeklik, A. (2001), Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 87(3), 177-180.
6. Schaefer, O. P. and Gore, J. M. (1999)Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 91(1), 8-13.
7. Ramanuja, S. J. Breall, A., and Kalaria, V. G. (2004), Approach to "aspirin allergy" in cardiovascular patients. Circulation 110(1), e1-e4.
8. Kasper, L., Sladek, K., Duplaga, M., et al. (2003), Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58(10), 1064-1066.
9. Jenkins, C., Costello, J., and Hodge, L. (2004), Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328(7437), 434.
10. Spector, S. L., Wangaard, C. H., and Farr, R. S. (1979), Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 64(6 Pt 1), 500-506.
11. McDonald, J. R., Mathison, D. A., and Stevenson, D. D. (1972), Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol 50(4), 198-207.
12. Zembowicz, A., Mastalerz, L., Setkowicz, M., Radziszewski, W., and Szczeklik, A. (2003), Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 139(12), 1577-1582.
13. Widal, F., Abrami, P., and Lermoyez, J. (1992), Anaphylaxie et idiosyncrasie. (Anaphylaxis and idiosyncrasy). Allergy Proc 14(5), 373-376; discussion 371,372.
14. Samter, M. and Beers, R. F., Jr. (1968), Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 68(5), 975-983.
15. Stevenson, D. D. and Mathison, D. A. (1985), Aspirin sensitivity in asthmatics. When may this drug be safe. Postgrad Med 78(3), 111-3, 116-119.
16. Berges-Gimeno, M. P., Simon, R. A., and Stevenson, D. D. (2002), The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 89(5), 474-478.
17. Szczeklik, A., Nizankowska, E., and Duplaga, M. (2000), Natural history of aspirin-induced asthma. AIANE Investigators, European Network on Aspirin-Induced Asthma. Eur Respir J 16(3), 432-436.
18. Stevenson, D. D. (2003), Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 24(2), 159-168.
19. Sousa, A. R., Parikh, A., Scadding, G., Corrigan, C. J., and Lee, T. H. (2002), Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 347(19), 1493-1699.
20. Sanak, M., Kielbasa, B., Bochenek, G., and Szczeklik, A. (2004), Exhaled eicosanoids following oral aspirin challenge in asthmatic patients. Clin Exp Allergy 34(12), 1899-1904.
21. Nasser, S. M., Patel, M., Bell, G. S., and Lee, T. H. (1995), The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 151(5), 1326-1330.
22. Stevenson, D. D. (1988), Oral challenges to detect aspirin and sulfite sensitivity in asthma. N Engl Reg Allergy Proc 9(2), 135-142.
23. Pauls, J. D., Simon, R. A., Daffern, P. J., and Stevenson, D. D. (2000), Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 85(1), 40-45.
24. Berges-Gimeno, M. P., Simon, R. A., and Stevenson, D. D. (2002), The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy 32(10), 1491-1496.
25. Wong, J. T., Nagy, C. S., Krinzman, S. J., Maclean, J. A., and Bloch, K. J. (2000), Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 105(5), 997-1001.
26. Blanca, M., Perez, E., Garcia, J. J., et al. (1989), Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 62(4), 295-298.
27. Vane, J. R., and Botting, R. M. (1998), Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104(3A), 2S-8S; discussion 21S,22S.
28. Asad, S. I., Kemeny, D. M., Youlten, L. J., Frankland, A. W., and Lessof, M. H. (1984), Effect of aspirin in "aspirin sensitive" patients. Br Med J (Clin Res Ed) 288(6419), 745-748.
29. Grzelewska-Rzymowska, I., Roznlecki, J., and Szmidt, M. (1988), Aspirin "desensitization" in patients with aspirin-induced urticaria and angioedema. Allergol Immunopathol (Madr) 16(5), 305-308.
30. Stevenson, D. D. (1986), Aspirin desensitization. N Engl Reg Allergy Proc 7(2), 101-104.
31. Simon, R. A. (2003), Prevention and treatment of reactions to NSAIDs. Clin Rev Allergy Immunol 24(2), 189-198.
32. Gollapudi, R. R., Teirstein, P. S., Stevenson, D. D., Simon, R. A. (2004), Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 292(24), 3017-3023.
33. Strom, B. L., Carson, J. L., Morse, M. L., West, S. L., Soper, K. A. (1987), The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum 30(10), 1142-1148.
34. Weber, J. C. and Essigman, W. K. (1986), Pulmonary alveolitis and NSAIDs - Fact or fiction. Br J Rheumatol 25, 5-6.
35. Nader, D. A. and Schillaci, R. F. (1983), Pulmonary infiltrates with eosinophilia due to naproxen. Chest 83(2), 280-282.
36. Marinac, J. S. (1992), Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann Pharmacother 26(6), 813-822.
37. Greenberg, G. N. (1988), Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs. South Med J 81(11), 1463,1464.
38. Hennekens, C. H., Dyken, M. L., and Fuster, V. (1997), Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96(8), 2751-2753.
39. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients (2002), BMJ 324(7329), 71-86.
40. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), CAPRIE Steering Committee (1996). Lancet 348(9038), 1329-1339.
41. Hermida, R. C., Ayala, D. E., Fernandez, J. R., et al. (1999), Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension 34(4 Pt 2), 1016-1023.
42. Gaspoz, J. M., Coxson, P. G., Goldman, P. A., et al. (2002), Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 346(23), 1800-1806.
43. Braunwald, E., Antman, E. M., Beasley, J. W., et al. (2000), ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 102(10), 1193-1209.
44. Steinhubl, S. R., Berger, P. B., Mann, J. T., 3rd, et al. (2002), Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420.
45. Yusuf, S., Zhao, F., Mehta, S. R., et al. (2001), Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7), 494-502.
46. Fattori, R. and Piva, T. (2003), Drug-eluting stents in vascular intervention. Lancet 361(9353), 247-249.
47. Morice, M. C., Serruys, P. W., Sousa, J. E., et al. (2002), A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346(23), 1773-1780.
48. Moses, J. W., Leon, M. B., Popma, J. J., et al. (2003), Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14), 1315-1323.
49. Namazy, J. A. and Simon, R. A. (2002), Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 89(6), 542-550; quiz 550, 605.
50. Machraoui, A., Germing, A., Lindstaedt, M., et al. (2001), Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. J Invasive Cardiol 13(6), 431-436.
51. Silberman, S., Neukirch-Stoop, C., and Steg, P. G. (2005), Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 95(4), 509-510.
52. Stevenson, D. D. (2001), Anaphylactic and anapylactoid reactions to aspirin and other nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 21(4), 745-768.
53. Stevenson, D. D., Pleskow, W. W., Simon, R. A., et al. (1984), Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 73(4), 500-507.
54. Berges-Gimeno, M. P., Simon, R. A., and Stevenson, D. D. (2003), Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 90(3), 338-341.
55. Wasiak, W. and Szmidt, M. (1999), A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma. Thorax 54(10), 900-904.
56. McHugh, S. M., Deighton, J., Stewart, A. G., Lachmann, P. J., and Ewan, P. W. (1995), Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 25(9), 828-838.
57. Zeiss, C. R. and Lockey, R. F. (1976), Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 57(5), 440-448.
58. Stevenson, D. D., Simon, R. A., and Mathison, D. A. (1980), Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 66(1), 82-88.
59. Pleskow, W. W., Stevenson, D. D., Mathison, D. A., Simon, R. A., Schatz, M., Zeiger, R. S., et al. (1982), Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 69(1 Pt 1), 11-19.
60. Sweet, J. M., Stevenson, D. D., Simon, R. A., Mathison, D. A. (1990), Long-term effects of aspirin desensitization - treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 85(1 Pt 1), 59-65.
61. Stevenson, D. D., Hankammer, M. A., Mathison, D. A., Christiansen, S. C., Simon, R. A. (1996), Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 98(4), 751-758.
62. Berges-Gimeno, M. P., Simon, R. A., and Stevenson, D. D. (2003), Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111(1), 180-186.